Copyright © 1998 by the European Society of Cardiology.
Uric acid in chronic heart failure: a marker of chronic inflammation
a Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
b Franz-Volhard-Klinik, Charité Berlin, Campus Berlin-Buch, Humboldt-University, Berlin, Germany
c Department of Anaesthesiology, Charité Berlin, Campus Berlin-Mitte, Humboldt-University, Berlin, Germany
accepted July 3, 1998
Background
Chronic heart failure is associated with hyperuricaemia and elevations in circulating markers of inflammation. Activation of xanthine oxidase, through free radical release, causes leukocyte and endothelial cell activation. Associations could therefore be expected between serum uric acid level, as a marker of increased xanthine oxidase activity, and markers of inflammation. We have explored these associations in patients with chronic heart failure, taking into account the hyperuricaemic effects of diuretic therapy and insulin resistance.
Methods and Results
Circulating uric acid and markers of inflammation were measured in 39 male patients with chronic heart failure and 16 healthy controls. All patients underwent a metabolic assessment, which provided a measure of insulin sensitivity (intravenous glucose tolerance tests and minimal modelling analysis). Compared to controls, patients with chronic heart failure had significantly higher levels of circulating uric acid, interleukin-6, soluble tumour necrosis factor receptor (sTNFR)-1, soluble intercellular adhesion molecule-1 (ICAM-1, allP<0·001), E-selectin and sTNFR2 (bothP<0·05). In patients with chronic heart failure, serum uric acid concentrations correlated with circulating levels of sTNFR1 (r=0·74), interleukin-6 (r=0·66), sTNFR2 (r=0·63), TNF
(r=0·60) (allP<0·001), and ICAM-1 (r=0·41,P<0·01). In stepwise regression analyses, serum uric acid emerged as the strongest predictor of ICAM-1, interleukin-6, TNF, sTNFR1 and sTNFR2, independent of diuretic dose, age, body mass index, alcohol intake, serum creatinine, plasma insulin and glucose, and insulin sensitivity.
Conclusions
Serum uric acid is strongly related to circulating markers of inflammation in patients with chronic heart failure. This is consistent with a role for increased xanthine oxidase activity in the inflammatory response in patients with chronic heart failure.
Key Words: Uric acid • chronic heart failure • cytokines • xanthine oxidase activity
f1 Correspondence: Dr Stefan D. Anker, Department of Cardiac Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, U.K. email: s.anker@ic.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Krishnan Hyperuricemia and Incident Heart Failure Circ Heart Fail, November 1, 2009; 2(6): 556 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Arora, P. Aukrust, T. Ueland, K. Broch, S. Simonsen, E. Gude, A. E. Fiane, O. Geiran, R. Wergeland, A. K. Andreassen, et al. Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality Eur J Heart Fail, October 1, 2009; 11(10): 1005 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bergamini, M. Cicoira, A. Rossi, and C. Vassanelli Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure Eur J Heart Fail, May 1, 2009; 11(5): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Krishnan, K. Svendsen, J. D. Neaton, G. Grandits, L. H. Kuller, and for the MRFIT Research Group Long-term Cardiovascular Mortality Among Middle-aged Men With Gout Arch Intern Med, May 26, 2008; 168(10): 1104 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, N. Leung, S. R. Zeldenrust, F. K. Buadi, R. A. Kyle, S. V. Rajkumar, and M. A. Gertz Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis Mayo Clin. Proc., March 1, 2008; 83(3): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Kutzing and B. L. Firestein Altered Uric Acid Levels and Disease States J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Christen, Z. Efstathiadou, E. Laspa, D. G. Johnston, and I. F. Godsland Rate of Change and Instability in Body Mass Index, Insulin Resistance, and Lipid Metabolism as Predictors of Atherosclerotic Vascular Disease J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3780 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gullu, D. Erdogan, M. Caliskan, D. Tok, S. Kulaksizoglu, A. Yildirir, and H. Muderrisoglu Elevated serum uric acid levels impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy Eur J Heart Fail, May 1, 2007; 9(5): 466 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Pascual-Figal, J. A. Hurtado-Martinez, B. Redondo, M. J. Antolinos, J. A. Ruiperez, and M. Valdes Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients Eur J Heart Fail, May 1, 2007; 9(5): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ruggiero, A. Cherubini, A. Ble, A. J.G. Bos, M. Maggio, V. D. Dixit, F. Lauretani, S. Bandinelli, U. Senin, and L. Ferrucci Uric acid and inflammatory markers Eur. Heart J., May 2, 2006; 27(10): 1174 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zoccali, R. Maio, F. Mallamaci, G. Sesti, and F. Perticone Uric Acid and Endothelial Dysfunction in Essential Hypertension J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1466 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kikura, T. Takada, and S. Sato Preexisting Morbidity as an Independent Risk Factor for Perioperative Acute Thromboembolism Syndrome Arch Surg, December 1, 2005; 140(12): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mellin, M. Isabelle, A. Oudot, C. Vergely-Vandriesse, C. Monteil, B. Di Meglio, J. P. Henry, B. Dautreaux, L. Rochette, C. Thuillez, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure Eur. Heart J., August 1, 2005; 26(15): 1544 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Reyes The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure Eur J Heart Fail, June 1, 2005; 7(4): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Ochiai, A. C.P. Barretto, M. T. Oliveira Jr., R. T. Munhoz, P. C. Morgado, and J. A.F. Ramires Uric acid renal excretion and renal insufficiency in decompensated severe heart failure Eur J Heart Fail, June 1, 2005; 7(4): 468 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Kelley, A. Trostchansky, H. Rubbo, B. A. Freeman, R. Radi, and M. M. Tarpey Binding of Xanthine Oxidase to Glycosaminoglycans Limits Inhibition by Oxypurinol J. Biol. Chem., September 3, 2004; 279(36): 37231 - 37234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kanellis, S. Watanabe, J. H. Li, D. H. Kang, P. Li, T. Nakagawa, A. Wamsley, D. Sheikh-Hamad, H. Y. Lan, L. Feng, et al. Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2 Hypertension, June 1, 2003; 41(6): 1287 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Anker, W. Doehner, M. Rauchhaus, R. Sharma, D. Francis, C. Knosalla, C. H. Davos, M. Cicoira, W. Shamim, M. Kemp, et al. Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging Circulation, April 22, 2003; 107(15): 1991 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Spieker, F. T. Ruschitzka, T. F. Luscher, and G. Noll The management of hyperuricemia and gout in patients with heart failure Eur J Heart Fail, August 1, 2002; 4(4): 403 - 410. [Full Text] [PDF]
|
|
|
|
|
|
C. A.J. Farquharson, R. Butler, A. Hill, J. J.F. Belch, and A. D. Struthers Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure Circulation, July 9, 2002; 106(2): 221 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Doehner, N. Schoene, M. Rauchhaus, F. Leyva-Leon, D. V. Pavitt, D. A. Reaveley, G. Schuler, A. J.S. Coats, S. D. Anker, and R. Hambrecht Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies Circulation, June 4, 2002; 105(22): 2619 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.Y.K. Wong, R.S. Macwalter, H.W. Fraser, I. Crombie, S.A. Ogston, and A.D. Struthers Urate predicts subsequent cardiac death in stroke survivors Eur. Heart J., May 2, 2002; 23(10): 788 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Sharma and S.D Anker From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D12 - D17. [Abstract] [PDF]
|
|
|
|
|
|
A.L. Clark, M. Loebe, E.V. Potapov, K. Egerer, C. Knosalla, R. Hetzer, and S.D. Anker Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight Eur. Heart J., December 2, 2001; 22(24): 2275 - 2283. [Abstract] [PDF]
|
|
|
|
|
|
S.G Williams, G.A Cooke, D.J Wright, W.J Parsons, R.L Riley, P Marshall, and L-B Tan Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure Eur. Heart J., August 2, 2001; 22(16): 1496 - 1503. [Abstract] [PDF]
|
|
|
|
 |
|
 W.S. Waring, D.J. Webb, and S.R.J. Maxwell Uric acid as a risk factor for cardiovascular disease QJM, November 1, 2000; 93(11): 707 - 713. [Full Text] [PDF]
|
|
|
|
|
|
P.P. Davey and H. Ashrafian New therapies for heart failure: is thalidomide the answer? QJM, May 1, 2000; 93(5): 305 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Poullis Serum Uric Acid and Cardiovascular Disease Risk Ann Intern Med, April 4, 2000; 132(7): 591 - 592. [Full Text] [PDF]
|
|
|
|
|
|
C Berry and A.L Clark Catabolism in chronic heart failure Eur. Heart J., April 1, 2000; 21(7): 521 - 532. [PDF]
|
|
|
|
 |
|
 D. F. Pauly and C. J. Pepine D-Ribose as a Supplement for Cardiac Energy Metabolism Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 249 - 258. [Abstract] [PDF]
|
|
|
|
|
|
M Piepoli Editorials: Diagnostic and prognostic indicators in chronic heart failure Eur. Heart J., October 1, 1999; 20(19): 1367 - 1369. [PDF]
|
|